In perhaps a grim reminder of the growing incidence of lifestyle diseases, five out of the top 10 largest-selling drugs in the country are now anti-diabetes, with the therapy registering a robust double-digit clip year-on-year.
The control of non-communicable diseases like diabetes poses one of the biggest challenges for the country's healthcare practitioners, even as the World Health Organization for the first time highlighted recently the need to step up prevention and treatment of the disease. A couple of years ago, only two-three diabetes drugs featured in the top-10 list of medicines (see chart). Also, top-selling drugs in the organised pharma retail market had largely been dominated by anti-invectives and antibiotics
Insulin brand Human Mixtard, oral formulation Glycomet GP , insulin Lantus, oral formulations Galvus Met and Janumet are now in the top-selling list of drugs in the country . Overall, the anti-diabetic therapy -estimated at nearly Rs 8,500 crore (moving annual total, or MAT for June 2016) -is the fifth-largest in the organized Pharma retail market, growing at a strong double-digit rate of 12%, data culled from market research firm AIOCD Awacs said.
Industry experts and doctors say that the huge sales uptick in diabetes medicines is due to multiple reasons. "The diabetes market has witnessed an upward trend based on new launches and detection cases, leading to a larger number of brands in the top 10 of the Indian pharmaceutical market," Hari Natarajan, vice-president of AIOCD Pharmasofttech Awacs, said. While the entry of a ne wer class of diabetes medicines (like gliptins) has contributed to the rise, there are certain external environment..